Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.
Journal: American journal of respiratory and critical care medicine
Published: August 08, 2025
Circulating biomarker results from a phase 2 study of seralutinib in pulmonary arterial hypertension.
Journal: American journal of respiratory and critical care medicine
Published: August 08, 2025
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Journal: The Lancet. Respiratory medicine
Published: September 28, 2023
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension.
Journal: International journal of molecular sciences
Published: June 28, 2023
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
Journal: The European respiratory journal
Published: August 27, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension.
Journal: Pulmonary circulation
Published: July 15, 2021
Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension.
Journal: Pulmonary circulation
Published: July 25, 2020
Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension.
Journal: Pulmonary circulation
Published: July 04, 2020
Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension.
Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension.
Journal: Pulmonary circulation
Published: June 11, 2020
Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium.
Journal: JACC. Basic to translational science
Published: May 05, 2020
SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
Journal: Pulmonary circulation
Published: February 17, 2020
Last Updated: 09/26/2026